Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
2.4
Journals
JCDD
Special Issues
Myocardial Infarction: Prevention, Treatment and Outcomes
share announcement

Myocardial Infarction: Prevention, Treatment and Outcomes

A special issue of Journal of Cardiovascular Development and Disease (ISSN 2308-3425).

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 3119

Special Issue Editors

Prof. Dr. Jacek Kubica

E-Mail Website
Guest Editor
Department of Cardiology and Internal Medicine, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-094 Bydgoszcz, Poland
Interests: internal medicine; cardiothoracic surgery (clinical training); myocardial infarction; acute heart failure; acute coronary syndrome; unstable angina pectoris
Dr. Piotr Adamski

E-Mail Website
Guest Editor
Department of Cardiology and Internal Medicine, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-094 Bydgoszcz, Poland
Interests: acute coronary syndrome; antiplatelet therapy; pharmacodynamics

Special Issue Information

Dear Colleagues,

Myocardial infarction is a leading cause of death worldwide, resulting from the interruption of myocardial blood flow and the consequent ischemia. Myocardial infarction is conditioned by numerous risks, such as smoking, hypertension, low-density lipoprotein (LDL) cholesterol, hyperlipidemia, diabetes, and so on. It is vital to take action in order to lower those risks and prevent myocardial infarction. In recent years, significant transformations have taken place in the treatment and outcomes of myocardial infarction. Currently, 95% of patients hospitalized with an MI survive due to improvements in the treatment techniques. Percutaneous coronary intervention is the main and most effective intervention. Drug-eluting stents or P2Y12 inhibitors have also demonstrated their substantial benefits to patients. However, drug duration and the incidence of reperfusion injury remain substantial challenges in the field.

This Special Issue aims to provide an open forum for those attempting to overcome these challenges, whether by reporting their research or by providing comments for review articles. We look forward to receiving your contributions.

Prof. Dr. Jacek Kubica
Dr. Piotr Adamski
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • myocardial infarction
  • coronary artery disease
  • percutaneous coronary intervention 
  • acute coronary syndrome
  • drug treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 596 KiB  
Article
Percutaneous Coronary Interventions with Sirolimus-Eluting Alex Plus Stents in Patients with or without Diabetes: 4-Year Results
by Jacek Bil, Maciej Tyczynski, Adam Kern, Krystian Bojko and Robert J. Gil
J. Cardiovasc. Dev. Dis. 2024, 11(6), 160; https://doi.org/10.3390/jcdd11060160 - 22 May 2024
Viewed by 1064
Abstract
We characterized the performance, as well as the safety, of a second-generation thin-strut sirolimus-eluting stent with a biodegradable polymer, Alex Plus (Balton, Poland), implanted in patients with type 2 diabetes (DM) with a 4-year follow-up. We defined the primary endpoint as the 48-month [...] Read more.
We characterized the performance, as well as the safety, of a second-generation thin-strut sirolimus-eluting stent with a biodegradable polymer, Alex Plus (Balton, Poland), implanted in patients with type 2 diabetes (DM) with a 4-year follow-up. We defined the primary endpoint as the 48-month rate of major cardiovascular adverse events (MACE), including cardiac death, myocardial infarction (MI), or target lesion revascularization (TLR). The secondary endpoints were all-cause death, cardiac death, MI, and TLR rates at 12, 24, 36, and 48 months. We enrolled 232 patients in whom 282 stents were implanted, including 97 DM and 135 non-DM patients. The mean age of the DM patients was 69.5 ± 10.1 years and females accounted for 30% of the patients. DM patients had higher rates of arterial hypertension (97% vs. 88%, p = 0.016), dyslipidemia (86% vs. 70%, p = 0.005), prior MI (61% vs. 40%, p = 0.002), prior PCI (65% vs. 50%, p = 0.020), and prior CABG (14% vs. 5.9%, p = 0.029). We recorded statistically significant differences for MACE (HR 1.85, 95% CI 1.01–3.41, p = 0.046), cardiac death (HR 4.46, 95% CI 1.44–13.8, p = 0.010), and MI (HR 3.17, 95% CI 1.10–9.12, p = 0.033), but not for TLR, between DM and non-DM patients in terms of the analyzed endpoints at 4 years. Our study showed that Alex Plus was efficient and safe in a contemporary cohort of real-world DM patients undergoing percutaneous revascularization. Full article
(This article belongs to the Special Issue Myocardial Infarction: Prevention, Treatment and Outcomes)
►▼ Show Figures

Figure 1

12 pages, 736 KiB  
Article
Structural Complications Following ST-Elevation Myocardial Infarction: An Analysis of the National Inpatient Sample 2016 to 2020
by Chun Shing Kwok, Adnan I. Qureshi, Maximillian Will, Konstantin Schwarz, Gregory Y. H. Lip and Josip A. Borovac
J. Cardiovasc. Dev. Dis. 2024, 11(2), 59; https://doi.org/10.3390/jcdd11020059 - 15 Feb 2024
Viewed by 1695
Abstract
ST-elevation myocardial infarction (STEMI) is a life-threatening emergency that can result in cardiac structural complications without timely revascularization. A retrospective study from the National Inpatient Sample included all patients with a diagnosis of STEMI between 2016 and 2020. Primary outcomes of interest were [...] Read more.
ST-elevation myocardial infarction (STEMI) is a life-threatening emergency that can result in cardiac structural complications without timely revascularization. A retrospective study from the National Inpatient Sample included all patients with a diagnosis of STEMI between 2016 and 2020. Primary outcomes of interest were in-hospital mortality, length of stay (LoS), and healthcare costs for patients with and without structural complications. There were 994,300 hospital admissions included in the analysis (median age 64 years and 32.2% female). Structural complications occurred in 0.78% of patients. There was a three-fold increase in patients with cardiogenic shock (41.6% vs. 13.6%) and in-hospital mortality (30.6% vs. 10.7%) in the group with structural complications. The median LoS was longer (5 days vs. 3 days), and the median cost was significantly greater (USD 32,436 vs. USD 20,241) for patients with structural complications. After adjustments, in-hospital mortality was significantly greater for patients with structural complications (OR 1.99, 95% CI 1.73–2.30), and both LoS and costs were greater. There was a significant increase in mortality with ruptured cardiac wall (OR 9.16, 95% CI 5.91–14.20), hemopericardium (OR 3.20, 95% CI 1.91–5.35), and ventricular septal rupture (OR 2.57, 95% CI 1.98–3.35) compared with those with no complication. In conclusion, structural complications in STEMI patients are rare but potentially catastrophic events. Full article
(This article belongs to the Special Issue Myocardial Infarction: Prevention, Treatment and Outcomes)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop